Available resources for the treatment of breast cancer in Mexico;Recursos disponibles para el tratamiento del cáncer de mama en México

Salud Publica de Mexico

Volumn 51, Issue SUPPL.2, 2009, Pages

  Mohar, Alejandro ^a   Bargalló, Enrique ^b   Ramírez, Ma Teresa ^b   Lara, Fernando ^b   Beltrán Ortega, Arturo ^b  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Breast; Cancer; Costs; Mexico; Treatment

Indexed keywords

ADULT; AGED; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; FEMALE; HEALTH CARE PLANNING; HUMAN; MEXICO; MIDDLE AGED; MULTICENTER STUDY; QUESTIONNAIRE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HEALTH RESOURCES; HUMANS; MEXICO; MIDDLE AGED; QUESTIONNAIRES; YOUNG ADULT;

EID: 77952567344     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2005. Cancer incidence and prevalence worldwide. Lyon: International agency for research on cancer (IARC), 2006.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108.
3. Di Leo A, Claudino W, Colangiuli D, Bessi S, Pestrin M, Biganzoli L. New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer. Ann Oncol 2007;18(S12):8-14.
4. Curado MP, Edwards b, Shin HR, (eds). Cancer Incidence in five continents Vol IX. Lyon, France: International Agency for Research on Cancer, 2007. (IARC Scientifica publications). [Consultado el 25-29 de septiembre de 2008]. Disponible en: http://www-dep.iarc.fr.
5. Registro Histopatológico de Neoplasias Malignas, 2003. México: Secretaría de Salud, 2007.
6. Frenk J, Gonzalez-Pier E, Gomez-Dantes O, Lezana MA, Knaul FM. Health system reform in Mexico 1. Comprehensive reform to improve health system performance in Mexico. Lancet 2006;368:1524-1534.
7. Knaul FM, Nigenda G, Lozano R, Arreola-Ornelas H, Langer A, Frenk J. Breast cancer in Mexico: a pressing priority. Reprod Health Matt 2008;16:1-11.
8. Piccart MJ, Procter M, Leylanu-Jones G, Goldhirsch, Untch M, Smith I, et al. Trastuzumab after adyuvant chemotharpy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
9. Porter P. Westernizing women's risk? Breast cancer in lower-income countries. N Eng J Med 2008;358:213-216.
10. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol 2007;25:180-186.
11. Ruiz-Godoy LM, comp. Biología molecular del cáncer. Clínicas Oncológicas de Iberoamérica. México: Planeación y Desarrollo Editorial, 2008.
12. Piccart-Gebhart MJ, Sotiriou C. Adjuvant chemotherapy -yes or no? Prognostic markers in early breast cancer. Ann Oncol 2007;18(S 12):2-7.
13. Wiggs DR. Radiation oncology in Australia: an increasing crisis. Australasian Radiol 2008;32:24-37.
14. Porter A, Aref A, Chodunsky Z, Elzway A, Manatrakul N, Ngoma T, et al. A global strategy for radiotherapy; a WHO consultation. Clinic Oncol (R Coll Radiol) 1999;11:368-370.
15. Pestalozzi B, Castiglione M. Primary Breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2)7-10.
16. NCCN Clinical Practice Guidelines in Oncology Breast Cancer. [Consultado el 25-27 de septiembre de 2008]. Disponible en: http://www.nccn.org/proffesionals/physician_gls/PDF/breast.pdf. Consultado en septiembre/25-27/2008.
17. Lozano R, Knaul FM, Gómez-Dantés H, et al. Tendencias en la mortalidad por cáncer de mama en México, 1979-2006. Observatorio de la Salud. Documento de Trabajo, Competitividad y Salud, Fundación Mex para la Salud, 2008.
18. Berry DA, Cronin KA, Plevritis SK. Effect of screening and adjuvant therapy on mortality from breast cancer. N Eng J Med 2005;353:1784-1792.
19. Glass A, Lacey JV, Carreon D, Hoover R. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography and estrogen receptor status. J Natl Cancer Inst 2007;99:1152-1161.
20. Cazap E, Buzaid AC, Grabino C, De la Garza J, Orlandi FJ, Scwartsmann G, et al. Breast cancer incidence in Latin America. Cancer 2008; 113(8 suppl):2359-2365.
21. Secretaría de Salud. Programa de Acción: cáncer de mama, 2007-2012. México: Secretaría de Salud, 2007.
22. Brandan ME, Villaseñor Y. Detección del cáncer de mama: Estado de la mamografía en México. Rev Inst Nal Cancerol 2006;1:147-162.
23. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000;321:624-628.
24. Ravdin PM, Cronin KA, Howlander MS, Berg CD, Chlebowski T, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-1674.
25. Poblano-Verástegui O, Figueroa-Perea JG, Lopez. Carrill L. institutional factors contributing to the utilization of breast clinical examination. Salud Pub Mex 2004;46:294-305.
26. Romieu I, Lazcano-Ponce E, Sanchez-Zamorano L. Willett W, Hernandez-Avila M. Carbohydates and the risk of breast cancer among Mexican women. Cancer Epidemiol Biom & Prev 2004;13:1283-1289.
27. Anderson BO, Shyyan R, Eniu A, Smith RA, Cheng-Har Y, Bese NS, et al. Breast cancer in limited-resource countries: An overview of the breast health global initiative 2055 Guidelines. Breast J 2006;12(suppl 1):S3-S15.